Net Cash Provided by (Used in) Financing Activities in USD of RIGEL PHARMACEUTICALS INC from 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
RIGEL PHARMACEUTICALS INC quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2015 to Q1 2025.
  • RIGEL PHARMACEUTICALS INC Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $484K.
  • RIGEL PHARMACEUTICALS INC annual Net Cash Provided by (Used in) Financing Activities for 2024 was -$11.6M, a 163% decline from 2023.
  • RIGEL PHARMACEUTICALS INC annual Net Cash Provided by (Used in) Financing Activities for 2023 was $18.4M, a 180% increase from 2022.
  • RIGEL PHARMACEUTICALS INC annual Net Cash Provided by (Used in) Financing Activities for 2022 was $6.55M, a 89.5% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

RIGEL PHARMACEUTICALS INC Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $484K +$3M 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025
Q1 2024 -$2.51M -$21.6M -113% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025
Q1 2023 $19.1M +$10.3M +117% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q1 2022 $8.8M +$6.7M +320% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023
Q1 2021 $2.1M +$761K +57% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022
Q1 2020 $1.34M +$1.32M 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021
Q1 2019 $16K* -$2M 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020
Q1 2018 $2.01M -$41.4M -95.4% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019
Q1 2017 $43.4M 01 Jan 2017 31 Mar 2017 10-Q 01 May 2018

RIGEL PHARMACEUTICALS INC Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$11.6M -$30M -163% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025
2023 $18.4M +$11.8M +180% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025
2022 $6.55M -$56.1M -89.5% 01 Jan 2022 31 Dec 2022 10-K 04 Mar 2025
2021 $62.7M +$50.1M +399% 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024
2020 $12.6M +$1.21M +10.6% 01 Jan 2020 31 Dec 2020 10-K 07 Mar 2023
2019 $11.4M -$60.5M -84.2% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 $71.9M -$45.8M -38.9% 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2021
2017 $118M +$92.5M +367% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020
2016 $25.2M +$18.1M +257% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019
2015 $7.05M 01 Jan 2015 31 Dec 2015 10-K 06 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.